The great majority of expert primary care HCPs who contributed to the outcomes reported here were confident or very confident that using CGM technology will become the standard of care for people with T2D on non‐intensive insulin therapy in primary care. The gene discussed is INS; the disease is type 2 diabetes mellitus.